Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M--Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M--EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IBB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IBBJohn Keeley 2015-09-30 Sold Out -0.01%$289.48 - $398
($359.64)
$ 256.24-29%Sold Out0
IBBGeorge Soros 2015-09-30 Sold Out -0.01%$289.48 - $398
($359.64)
$ 256.24-29%Sold Out0
IBBGeorge Soros 2015-06-30 Buy 0.01%$333.61 - $383.19
($358.63)
$ 256.24-29%New holding2,400
IBBJohn Keeley 2014-12-31 Buy 0.01%$255.27 - $308.01
($283.24)
$ 256.24-10%New holding905
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IBB is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IBB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sartor, RobertSenior Officer 2016-02-05Buy1,400$5.354689.53view
Arrow Capital Management Inc.Director or Senior Officer of Insider or Subsidiar 2016-02-05Buy1,000$5.54558.91view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell19,600$18.951252.19view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell19,700$18.961251.48view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell5,600$18.971250.76view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell12,700$191248.63view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell2,900$18.991249.34view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell2,100$19.051245.09view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell1,600$19.031246.51view
Martin, Paul DouglasDirector, Senior Officer 2016-02-05Sell1,900$19.021247.21view

Press Releases about IBB :

Quarterly/Annual Reports about IBB:

    News about IBB:

    Articles On GuruFocus.com
    Mario Gabelli Adds More Shares in Comcast Feb 07 2016 
    Weekly CFO Buys Highlight: Radian Group, Zions Bancorp, Talmer Bancorp Feb 07 2016 
    Seth Klarman Finds Hidden Value in Pharmaceutical Company Feb 07 2016 
    Lululemon: What Is Steve Mandel's Thesis? Feb 07 2016 
    Donald Yacktman Increases America's Car-Mart Holding Feb 07 2016 
    Lou Simpson Adds to Valeant Stake Feb 07 2016 
    Mr. Market and a Valuation of the Dow Jones Industrial Average - February Feb 07 2016 
    Spirit Airlines' Low Cost Advantage Positioned for Long-Term Profitability Feb 07 2016 
    Incompetent Management May Kill GoPro Feb 07 2016 
    Yacktman Fund Comments on Staples Feb 05 2016 

    More From Other Websites
    Tough end to the week for tech Feb 05 2016
    Biotech stocks too risky? Feb 05 2016
    Gilead Sciences: Why Slowing Hep-C Sales Don't Matter Feb 05 2016
    Shkreli's attorney: He's been unfairly vilified Feb 04 2016
    It’s Time to Buy This Biotech Gem Feb 04 2016
    TickerTags Data Shows Drug Price Debate Still Trending Feb 03 2016
    Michael Kors -- On Its Way to $60? Feb 03 2016
    Dividend Growth ‘Bubble’ To Continue But For How Long? Feb 03 2016
    An overview on the biotech sector: Pro Feb 02 2016
    Economic implications from the Iowa caucuses Feb 02 2016
    Jim Cramer: Stop Thinking So Short Term About Biotech Stocks Feb 01 2016
    Tracking The Biotech Bubble's Bust Jan 31 2016
    Sunday links: better off de-risking Jan 31 2016
    When This Happens Stocks Could Drop At An Unprecedented Rate Jan 30 2016
    If history rhymes this indicator suggests stocks still have a long way to fall Jan 29 2016
    Maybe Some Good News For A Big Biotech ETF Jan 29 2016
    The Majority of Brokers Recommend a “Buy” for Mylan Jan 28 2016
    Like big pharma, biotech is toxic: Trader Jan 28 2016
    Relypsa Results Surprise Wall Street Jan 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK